BioCentury | Apr 29, 2020
Product Development

Clover becomes latest COVID-19 vaccine developer to gain CEPI funding as Moderna, Jenner continue to advance

Amid a flurry of COVID-19 vaccine updates, CEPI has announced an investment in Clover that will support its advancement into the clinic. On the treatment front, Pneumagen reported preclinical antiviral activity for its lead program,...
BioCentury | Feb 13, 2020
Emerging Company Profile

Pneumagen: out-competing viral sugar binding to prevent infection

With its platform of carbohydrate-binding proteins, Pneumagen is co-opting a pathogenic tool for interacting with host cells to block infections and adapting the technology for use against cancer. Both viruses and bacteria can interact with...
Items per page:
1 - 2 of 2
BioCentury | Apr 29, 2020
Product Development

Clover becomes latest COVID-19 vaccine developer to gain CEPI funding as Moderna, Jenner continue to advance

Amid a flurry of COVID-19 vaccine updates, CEPI has announced an investment in Clover that will support its advancement into the clinic. On the treatment front, Pneumagen reported preclinical antiviral activity for its lead program,...
BioCentury | Feb 13, 2020
Emerging Company Profile

Pneumagen: out-competing viral sugar binding to prevent infection

With its platform of carbohydrate-binding proteins, Pneumagen is co-opting a pathogenic tool for interacting with host cells to block infections and adapting the technology for use against cancer. Both viruses and bacteria can interact with...
Items per page:
1 - 2 of 2